SUPPLEMENTAL MATERIAL

Hypertensive diseases in pregnancy and kidney function later in life: The Genetic Epidemiology Network of Arteriopathy (GENOA) study.

Adebamike A. Oshunbade; Seth T. Lirette; B. Gwen Windham; Tariq Shafi; Arsalan Hamid; Semiu O. Gbadamosi; Adrienne Tin;

Wondwosen K. Yimer; Martin Tibuakuu; Donald Clark III; Daisuke Kamimura; Elizabeth A. Lutz; Robert J. Mentz; Ervin R. Fox;

Javed Butler; Kenneth R. Butler; Vesna D. Garovic; Stephen T. Turner; Thomas H. Mosley Jr.; Michael E. Hall

Table of Contents

Supplemental TABLE 1: Differences in eGFR <60 ml/1.73m^2 Later in Life Across Pregnancy History categories with Normotensive pregnancies as the reference group *

Model	Normotensive pregnancy	Nulliparous	Hypertensive pregnancy	Preeclamptic Pregnancy
Unadjusted	reference	-4.79 (-15.98, 6.38) *P*=.40	**-12.66 (-21.32, -4.00) *P*<.01**	-13.55 (-34.60, 7.50) *P*= .21
Model 1	reference	-4.76 (-15.42,5.90) *P*=.38	**-13.01 (-21.14, -4.7) *P*<.01**	-11.55 (-31.17, 8.05) *P*=.25
Model 2	reference	-4.22 (-13.04,4.59) *P*=.35	**-9.13 (-17.27, -0.99) *P*=.03**	-6.88 (-20.36, 6.60) *P*=.32

All values for Cystatin C Estimated GFR are expressed as adjusted β coefficients, with 95% confidence intervals and *P*-values; *P*-values in bold are significant; Model 1: adjusted for age and race; Model 2: plus level of education, smoking history, hypertension, Body Mass Index (BMI), and diabetes

* mean age of the participants at the time of kidney function measurements was 59 ± 9 years

Supplemental TABLE 2: Odds of eGFR <60 ml/1.73m^2 Later in Life Across Pregnancy Groups with Normotensive pregnancies as the reference group*

Model	Normotensive pregnancy	Nulliparous	Hypertensive pregnancy	Preeclamptic Pregnancy
Unadjusted	1 (Reference)	1.46 (0.72, 2.95) *P*=.29	**2.04 (1.26, 3.32) *P*<.01**	**2.99 (1.06, 8.41) *P*=.04**
Model 1	1 (Reference)	1.89 (0.88, 4.02) *P*=.10	**2.24 (1.35, 3.70) *P*<.01**	**3.56 (1.05, 12.01) *P*=.04**
Model 2	1 (Reference)	1.89 (0.90, 3.96) *P*=.09	**1.86 (1.06, 3.25) *P*=.03**	2.61 (0.86, 7.87) *P*=.09

All values for Cystatin C Estimated GFR are expressed as adjusted OR, Odds ratios, with 95% confidence intervals and *P*-values; *P*-values in bold are significant; Model 1: adjusted for age and race; Model 2: plus level of education, smoking history, hypertension, Body Mass Index (BMI), and diabetes

* mean age of the participants at the time of kidney function measurements was 59 ± 9 years

Supplemental TABLE 3: Distribution of Abnormal Kidney function measurements Across Pregnancy Groups

	Normotensive Pregnancy	**Nulliparous**	**Hypertensive Pregnancy**	**Preeclamptic Pregnancy**
mGFR < 60	85	9	27	4
eGFR < 60	67	10	24	5
**UACR > 30 mg/g Cr	41	1	10	

* represents the number of participants with UACR>30mg/g Cr among our analytical cohort (n=380) that had available data on UACR; eGFR was estimated using cystatin C

Supplemental Table 4: Differences in mGFR <60 ml/1.73m^2 Later in Life in women classified as having history of HDP compared with Normotensive pregnancies *

Model	Normotensive pregnancy	Nulliparous	HDP
Unadjusted	reference	3.06 (-2.63, 8.75) *P*=.29	**-5.09 (-9.38, -0.80) *P*=.02**
Model 1	reference	-1.46 (-6.96,4.03) *P*=.60	**-5.46 (-9.68, -1.03) *P*<.01**
Model 2	reference	-1.14 (-6.64,4.35) *P*=.68	**-4.78 (-8.97, -0.58) *P*=.03**

All values for mGFR are expressed as adjusted β coefficients, with 95% confidence intervals and *P*-values; *P*-values in bold are significant; Model 1: adjusted for age and race; Model 2: plus level of education, smoking history, hypertension, Body Mass Index (BMI), and diabetes ; HDP represents Hypertensive diseases in pregnancy (history of hypertensive pregnancy or history of preeclampsia combined as a single group)

* mean age of the participants at the time of kidney function measurements was 59 ± 9 years

Supplemental Table 5: Odds of mGFR <60 ml/1.73m^2 Later in Life in women classified as having history of HDP compared with Normotensive pregnancies *

Model	Normotensive pregnancy	Nulliparous	HDP
Unadjusted	1 (reference)	0.95 (0.47, 1.93) *P*=.91	**1.87 (1.16, 3.03) *P*=.01**
Model 1	1 (reference)	1.38 (0.67, 2.86) *P*=.37	**2.01 (1.23, 3.29) *P*<.01**
Model 2	1 (reference)	1.49 (0.73, 3.06) *P*=.27	**2.09 (1.24, 3.52) *P*<.01**

All values for mGFR are expressed as adjusted OR, Odds ratios, with 95% confidence intervals and *P*-values; *P*-values in bold are significant; Model 1: adjusted for age and race; Model 2: plus level of education, smoking history, hypertension, Body Mass Index (BMI), and diabetes ; HDP represents Hypertensive diseases in pregnancy (history of hypertensive pregnancy or history of preeclampsia combined as a single group)

* mean age of the participants at the time of kidney function measurements was 59 ± 9 years

Supplemental Table 6: Odds of Chronic Kidney Disease (CKD) Later in Life in women classified as having history of HDP *

Model	Normotensive pregnancy	Nulliparous	HDP
Unadjusted	1 (reference)	2.32 (0.26, 20.43) *P*=.45	**4.50 (1.46, 13.84) *P*<.01**
Model 1	1 (reference)	2.44 (0.27, 21.54) *P*=.42	**4.38 (1.41, 13.56) *P*<.01**
Model 2	1 (reference)	2.26 (0.27, 18.88) *P*=.45	**3.97 (1.32, 11.90) *P*<.01**

n=387; All values for mGFR are expressed as adjusted OR, Odds ratios, with 95% confidence intervals and *P*-values; *P*-values in bold are significant;

Model 1:adjusted for age and race; Model 2: plus level of education, smoking history, hypertension, Body Mass Index (BMI), and diabetes ; HDP represents Hypertensive diseases in pregnancy (history of hypertensive pregnancy or history of preeclampsia combined as a single group)

*CKD defined as mGFR <60 ml/min/1.73 m^2 or UACR ≥30 mg/g

** mean age of the participants at the time of kidney function measurements was 59 ± 9 years

Supplemental Figure

Plots for adjusted average measures of kidney function with 95% confidence bands across pregnancy history categories (from Model 2)

NP- Nulliparous; NTN-Normotensive Pregnancy; HTN-Hypertensive pregnancy; PE-Preeclamptic Pregnancy